A Randomized, Multicentre, Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
← catalyst calendarNCT07768189 · readout ≤ 499 d
Sponsored by Corbus Pharmaceuticals Inc. (industry) · CRBP — their whole pipeline →. With CSPC Megalith Biopharmaceutical Co.,Ltd..
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
260estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-20 | estimated | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Oropharyngeal Carcinoma (OPC)
Interventions
- Drug: CRB-701
- Drug: capcitabine
- Drug: Cetuximab (EGFR inhibitor)
- Drug: Docetaxel
Primary outcomes
what the primary-completion date above is the date OFObjective Response Rate (%)
measured Up to 24 months
Overall Survival (months)
measured Approximately 3 years from randomization
Permalink · CRBP's whole pipeline · Catalyst calendar · Every registered study · What changed